Changing the landscape of tumor immunology: novel tools to examine T cell specificity

Rahman, Muhammed A.; Murata, Kenji; Burt, Brian D; Hirano, Naoto

doi:10.1016/j.coi.2020.11.003

Search citation statements

Order By: Relevance

Paper Sections

Select...

Tcr-engineered T Cells1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using this rationale [ 104 ], they further identified shared antigenic epitopes recognized by melanoma TILs and their cloned TCRs, for the development of novel cancer immunotherapy [ 103 ]. This, certainly changes the landscape of tumour immunotherapy [ 105 ].…”

Section: Tcr-engineered T Cellsmentioning

confidence: 99%

Recent advances in cancer immunotherapy

et al. 2021

View full text Add to dashboard Cite

Cancer immunotherapy represents a major advance in the cure of cancer following the dramatic advancements in the development and refinement of chemotherapies and radiotherapies. In the recent decades, together with the development of early diagnostic techniques, immunotherapy has significantly contributed to improving the survival of cancer patients. The immune-checkpoint blockade agents have been proven effective in a significant fraction of standard therapy refractory patients. Importantly, recent advances are providing alternative immunotherapeutic tools that could help overcome their limitations. In this mini review, we provide an overview on the main steps of the discovery of classic immune-checkpoint blockade agents and summarise the most recent development of novel immunotherapeutic strategies, such as tumour antigens, bispecific antibodies and TCR-engineered T cells.

show abstract

Section: Tcr-engineered T Cellsmentioning

confidence: 99%